Opendata, web and dolomites

OPVANOX-ARDS SIGNED

Advanced pulmonary vascular monitoring for optimum Nitric Oxide delivery in acute respiratory distress syndrome. Expanding Nitric Oxide applications

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 OPVANOX-ARDS project word cloud

Explore the words cloud of the OPVANOX-ARDS project. It provides you a very rough idea of what is the project "OPVANOX-ARDS" about.

tools    models    imaging    skills    severe    career    biologic    business    animal    performance    physiology    company    vascular    proven    clinically    turning    form    acquire    patients    acute    edge    emission    benefit    pulmonary    academy    variables    competitive    waveform    combine    outcomes    gas    monitoring    therapies    distress    enterprise    oxide    monitors    dysfunction    quantitative    inhaled    technologies    positron    patient    guide    industry    positioned    minimum    algorithms    prognosis    treatment    lack    incorporation    physiologic    mortality    representative    companies    dose    expertise    artery    tomography    magnetic    expecting    efficient    gain    safety    worldwide    algorithm    software    ards    syndrome    uncontrolled    efficiency    bedside    respiratory    entails    nitric    involve    mechanics    administration    delivering    clinical    expanding    of    improves    invasive    resonance    despite    clear    effect    researcher    oriented    pressure   

Project "OPVANOX-ARDS" data sheet

The following table provides information about the project.

Coordinator
INGENIERIA Y TECNICAS CLINICAS SA 

Organization address
address: CALLE TUNGSTENO 11-13
city: ARGANDA DEL REY - MADRID
postcode: 28500
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Total cost 158˙121 €
 EC max contribution 158˙121 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2017
 Funding Scheme MSCA-IF-EF-SE
 Starting year 2018
 Duration (year-month-day) from 2018-05-01   to  2020-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    INGENIERIA Y TECNICAS CLINICAS SA ES (ARGANDA DEL REY - MADRID) coordinator 158˙121.00

Map

 Project objective

Acute respiratory distress syndrome (ARDS) is the most severe form of respiratory failure. Pulmonary vascular dysfunction during ARDS increases mortality and therapies focused in improving pulmonary vascular mechanics could improve patient prognosis. Inhaled Nitric Oxide (NO), improves pulmonary vascular mechanics, but despite of this effect, has not proven to improve outcomes in ARDS. One of the most representative problems is the lack of information of the quantitative dose used and all consequences that this uncontrolled administration entails. In this project we aim to establish bedside physiologic variables and algorithms to guide efficient NO delivery during ARDS. It will involve the collaboration between an enterprise that has developed a new NO delivering system and is looking for expanding its applications and a researcher with expertise in physiology, imaging and biologic variables monitoring. As a result of this collaboration, the company will gain a quantitative way of determining the treatment efficiency that could be used in this and other applications, a more patient-oriented and physiology-focused approach for this product and the researcher will acquire skills for turning his career from the academy to the industry side. This research will combine edge technology to define bedside tools for patients monitoring with the application of this information for improving the performance of the delivery system. Clinically relevant imaging tools such as Magnetic Resonance Imaging and Positron Emission Tomography, and pulmonary artery pressure waveform advanced analysis as well as other non or minimum invasive tools will be studied in animal models. Software, algorithm or dedicated products will be proposed for incorporation into the gas delivery system or clinical monitors for improving patient safety. We are expecting a clear benefit to emerging European-based technologies that make our companies more competitive and well-positioned in a worldwide business.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "OPVANOX-ARDS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "OPVANOX-ARDS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

MY MITOCOMPLEX (2021)

Functional relevance of mitochondrial supercomplex assembly in myeloid cells

Read More  

LUNG-BIM (2019)

Induction of B cell immunity in the lung mucosa

Read More  

RipGEESE (2020)

Identifying the ripples of gene regulation evolution in the evolution of gene sequences to determine when animal nervous systems evolved

Read More